Akebia Therapeutics
Stock Forecast, Prediction & Price Target
Akebia Therapeutics Financial Estimates
Akebia Therapeutics Revenue Estimates
Akebia Therapeutics EBITDA Estimates
Akebia Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $213.57M N/A | $292.60M 37.00% | $194.62M -33.48% | Avg: $159.37M Low: $136.43M High: $182.32M avg. -18.10% | Avg: $237.17M Low: $212.95M High: $258.22M avg. 48.80% | Avg: $327.45M Low: $294.01M High: $356.52M avg. 38.06% | Avg: $444.01M Low: $398.67M High: $483.43M avg. 35.59% |
Net Income
% change YoY
| $-244.87M N/A | $-106.00M 56.70% | $-51.92M 51.01% | Avg: $-73.31M Low: $-108.72M High: $14.99M avg. -41.19% | Avg: $37.77M Low: $-22.49M High: $76.86M avg. 151.52% | Avg: $92.79M Low: $80.47M High: $103.50M avg. 145.63% | Avg: $192.15M Low: $166.64M High: $214.33M avg. 107.07% |
EBITDA
% change YoY
| $-265.31M N/A | $-46.34M 82.53% | $-6.86M 85.18% | Avg: $-96.73M Low: $-110.65M High: $-82.80M avg. -1308.46% | Avg: $-143.94M Low: $-156.72M High: $-129.24M avg. -48.80% | Avg: $-198.74M Low: $-216.38M High: $-178.44M avg. -38.06% | Avg: $-269.48M Low: $-293.41M High: $-241.97M avg. -35.59% |
EPS
% change YoY
| -$1.48 N/A | -$0.58 60.81% | -$0.28 51.72% | Avg: -$0.33 Low: -$0.58 High: $0.08 avg. -16.66% | Avg: $0.15 Low: -$0.12 High: $0.41 avg. 144.38% | Avg: $0.5 Low: $0.43 High: $0.55 avg. 241.37% | Avg: $1.03 Low: $0.89 High: $1.14 avg. 107.07% |
Operating Expenses
% change YoY
| $325.50M N/A | $270.98M -16.74% | $166.73M -38.47% | Avg: $89.23M Low: $76.38M High: $102.07M avg. -46.48% | Avg: $132.78M Low: $119.22M High: $144.57M avg. 48.80% | Avg: $183.33M Low: $164.61M High: $199.61M avg. 38.06% | Avg: $248.59M Low: $223.20M High: $270.66M avg. 35.59% |
FAQ
What is Akebia Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 90.75% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -108.72M, average is -73.31M and high is 14.99M.
What is Akebia Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 26.09% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $136.43M, average is $159.37M and high is $182.32M.
What is Akebia Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 119.04% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.58, average is -$0.33 and high is $0.08.
What is the best performing analyst?
In the last twelve months analysts have been covering Akebia Therapeutics stock. The most successful analyst is Ed Arce.